From various sources including the FDA's websites:
The Food and Drug Administration issued a non-approvable letter for parecoxib sodium, an injectable COX-2 inhibitor. Parecoxib sodium is marketed by Pfizer under the brand name Dynastat.
It is to be administered for short periods of time under the supervision of a health-care professional.
